dabigatran etexilate + digoxin

This is a **combination of dabigatran etexilate and digoxin**. Dabigatran etexilate is an oral prodrug that, once hydrolyzed, becomes dabigatran, a direct, reversible thrombin (factor IIa) inhibitor used as an anticoagulant to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation and to treat or prevent deep vein thrombosis and pulmonary embolism. Digoxin is a cardiac glycoside that inhibits sodium-potassium ATPase, increasing intracellular calcium and enhancing cardiac contractility; it is mainly used for heart failure and certain arrhythmias. There is no significant pharmacokinetic or pharmacodynamic interaction between dabigatran etexilate and digoxin, and they can be coadministered without dose adjustments[4][2][6].